Deferred Tax Assets, Operating Loss Carryforwards of Inozyme Pharma, Inc. from 31 Dec 2019 to 31 Dec 2024

Taxonomy & unit: us-gaap: USD
Description: Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary: Inozyme Pharma, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD history and change rate from 31 Dec 2019 to 31 Dec 2024.
Inozyme Pharma, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 31 Dec 2024 was $52,767,000, a 23% increase year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)

Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

Inozyme Pharma, Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2024	$52,767,000	+$9,768,000	+23%	31 Dec 2024	10-K	10 Mar 2025	2024	FY
Q4 2023	$42,999,000	+$6,855,000	+19%	31 Dec 2023	10-K	10 Mar 2025	2024	FY
Q4 2022	$36,144,000	+$5,034,000	+16%	31 Dec 2022	10-K	12 Mar 2024	2023	FY
Q4 2021	$31,110,000	+$13,398,000	+76%	31 Dec 2021	10-K	22 Mar 2023	2022	FY
Q4 2020	$17,712,000	+$9,128,000	+106%	31 Dec 2020	10-K	15 Mar 2022	2021	FY
Q4 2019	$8,584,000			31 Dec 2019	10-K	25 Mar 2021	2020	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.